Comprehensive Pan-Cancer Analysis Reveals the Potential Biological, Immunological, and Prognostic Value of NKG2A
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive Pan-Cancer Analysis Reveals the Potential Biological, Immunological, and Prognostic Value of NKG2A
Authors
Keywords
-
Journal
Analytical Cellular Pathology
Volume 2023, Issue -, Pages 1-28
Publisher
Hindawi Limited
Online
2023-10-22
DOI
10.1155/2023/2211942
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer
- (2022) Takeshi Morinaga et al. ANNALS OF SURGICAL ONCOLOGY
- NKG2A‐checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA‐E
- (2022) Claire Battin et al. IMMUNOLOGY
- NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
- (2022) Sen Yan et al. Journal for ImmunoTherapy of Cancer
- Implications of NKG2A in immunity and immune-mediated diseases
- (2022) Xiaotong Wang et al. Frontiers in Immunology
- NK cell-based cancer immunotherapy: from basic biology to clinical development
- (2021) Sizhe Liu et al. Journal of Hematology & Oncology
- Natural killer cell exhaustion in lung cancer
- (2021) Qi Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions
- (2021) Valentina Cazzetta et al. Cell Reports
- Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro
- (2021) Daniela J. Carroll et al. Frontiers in Immunology
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NK Cell-Based Immune Checkpoint Inhibition
- (2020) Muhammad Khan et al. Frontiers in Immunology
- The NKG2A - HLA-E axis as a novel checkpoint in the tumor microenvironment
- (2020) Linda Borst et al. CLINICAL CANCER RESEARCH
- Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
- (2020) Florian Moik et al. BLOOD
- Exploring the NK cell platform for cancer immunotherapy
- (2020) Jacob A. Myers et al. Nature Reviews Clinical Oncology
- High Metabolic Function and Resilience of NKG2A-Educated NK Cells
- (2020) Andrew J. Highton et al. Frontiers in Immunology
- The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
- (2020) Denis L. Jardim et al. CANCER CELL
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Human liver-derived CXCR6+ NK cells are predominantly educated through NKG2A and show reduced cytokine production
- (2019) Sebastian Lunemann et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
- (2019) Simona Sivori et al. Cellular & Molecular Immunology
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Monalizumab: inhibiting the novel immune checkpoint NKG2A
- (2019) Thorbald van Hall et al. Journal for ImmunoTherapy of Cancer
- PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
- (2019) Tugba Akin Telli et al. CANCER LETTERS
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Analysis of DNA methylation in cancer: location revisited
- (2018) Alexander Koch et al. Nature Reviews Clinical Oncology
- First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.
- (2018) Neil Howard Segal et al. JOURNAL OF CLINICAL ONCOLOGY
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- (2018) Nadine van Montfoort et al. CELL
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
- (2016) Cheng Sun et al. OncoImmunology
- The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma
- (2015) Mehrdad Talebian Yazdi et al. Oncotarget
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Microsatellite instability in colorectal cancer—the stable evidence
- (2010) Eduardo Vilar et al. Nature Reviews Clinical Oncology
- HLA-E and HLA-E-Bound Peptides: Recognition by Subsets of NK and T Cells
- (2009) Gabriella Pietra et al. CURRENT PHARMACEUTICAL DESIGN
- Hepatocytes and IL-15: A Favorable Microenvironment for T Cell Survival and CD8 + T Cell Differentiation
- (2009) Margareta P. Correia et al. JOURNAL OF IMMUNOLOGY
- Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells
- (2008) S. Chattopadhyay et al. INTERNATIONAL IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now